Drug Trial Radar · NCT07131254
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors
Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Mar 10, 2025
Primary completion
Dec 1, 2027
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- Collaborators
- Ganzhou City People's Hospital
- First posted
- Aug 20, 2025
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in relapsed/refractory CD19 positive adult B-cell non Hodgkin lymphoma (B-NHL) and B-acute lymphoblastic leukemia (B-ALL) patients. A total of 34 subjects will be enrolled in this study.
Conditions
- Hematological Malignancy (Leukemia- Lymphoma)
Interventions
GT719 InjectionBiological
GT719 Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: 28 days
- Proportion of participants experiencing dose limiting toxicityTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ganzhou City People's Hospital
Ganzhou, Jiangxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.